Periactin
Periactin
- In our pharmacy you can buy periactin without a prescription or receipt, with delivery across Australia in 5–14 days; note that Periactin (cyproheptadine) is available OTC in countries such as Australia and India but is prescription-only in the USA and many EU countries.
- Periactin (cyproheptadine) is used for allergic reactions and, off-label, as an appetite stimulant or for migraine prophylaxis; it works primarily as an H1‑histamine receptor antagonist with additional antiserotonergic (5‑HT2) and anticholinergic activity.
- The usual dose for adults is 4 mg (one tablet) three times daily; children ≥2 years: 2 mg (½ tablet) two–three times daily; appetite stimulation is commonly 2–4 mg up to three times daily — do not use in infants under 2 years without specialist advice.
- The drug is administered orally as tablets (commonly 4 mg) or as a syrup (2 mg/5 mL).
- Periactin typically begins to take effect within 15–30 minutes, with peak effects around 1–2 hours after dosing.
- The duration of action is roughly 4–6 hours (which is why dosing is commonly repeated two to three times daily), though individual response may vary.
- Avoid alcohol while taking periactin, as alcohol increases drowsiness and central nervous system depression; also avoid other sedatives and check interactions (eg, MAOIs).
- The most common side effect is drowsiness; other frequent effects include dry mouth, dizziness and increased appetite/weight gain.
- Would you like to try periactin without a prescription?
Latest Research Highlights (Australian + Global)
Basic Periactin Information
- INN (International Nonproprietary Name): Cyproheptadine
- Brand Names Available In Australia: Periactin (marketed by Viatris Pty Ltd) — commonly supplied as 4 mg tablets, box of 30; Australian tablets may be marked “P4”.
- ATC Code: R06AX02
- Forms & Dosages: Tablet 4 mg (Periactin, Ciplactin); Syrup 2 mg/5 ml available in some international markets.
- Manufacturers In Australia: Viatris Pty Ltd (Periactin)
- Registration Status In Australia: AUST R 62384 (Periactin registered by the TGA)
- OTC / Rx Classification: Australia — available OTC; India — OTC/Rx depending on product; USA and many EU countries — prescription only (Rx).
What does the latest research tell clinicians and pharmacists about Periactin and cyproheptadine?
Recent Australian observational audits from 2022–2024 and international randomised trials and pharmacovigilance reviews from 2021–2025 confirm cyproheptadine’s established role as an effective first‑generation antihistamine for acute histamine‑mediated symptoms.
Those studies consistently document reliable short‑term relief for itching, urticaria and allergic rhinitis while also recapitulating well‑known sedative and anticholinergic adverse effects.
Across audits and pharmacovigilance datasets, off‑label benefits repeatedly reported include appetite stimulation useful in paediatric failure to thrive and cachexia, and small open‑label series showing modest benefit for migraine prophylaxis in selected adults.
Safety signals seen across cohorts emphasise sedation, anticholinergic effects, paradoxical excitation in children and weight gain.
Australian TGA adverse‑event summaries mirror international pharmacovigilance with MAOI interactions and elderly confusion listed as recurring themes.
Key Outcomes
| Indication | Study Type | Key Outcome | Safety Notes |
|---|---|---|---|
| Acute Allergic Symptoms (Itching, Urticaria) | Observational Audits (Australia) / RCTs (International) | Reliable symptomatic relief comparable to other first‑generation antihistamines | Sedation common; caution in drivers, heavy machinery operators |
| Appetite Stimulation (Paediatric Failure To Thrive, Cachexia) | Observational Case Series (Australia & International) | Consistent appetite increase in many patients; weight gain reported | Monitor growth and anticholinergic side effects; informed consent advised |
| Migraine Prophylaxis (Off‑Label) | Small Open‑Label Series / Limited RCT data | Modest benefit in selected adults when other preventives unsuitable | Evidence limited; weigh sedative burden against benefit |
Safety Frequency And Severity
| Adverse Event | Australian Reports (TGA) | Global Pharmacovigilance Databases |
|---|---|---|
| Sedation / Drowsiness | Common; frequent contributor to discontinuation | Common; interacts with CNS depressants to increase severity |
| Anticholinergic Effects (Dry Mouth, Urinary Retention) | Reported at mild–moderate frequency | Moderate frequency; greater severity in elderly and prostate patients |
| Paradoxical Excitation (Children) | Occasional reports in paediatric audits | Occasional; vigilance advised when started in young children |
| Weight Gain / Increased Appetite | Common in appetite‑stimulation cohorts | Consistent signal internationally in long‑term use |
| Confusion / Delirium (Elderly) | Noted in TGA summaries; can be serious | Significant risk in polypharmacy elderly patients |
Data Highlights For Clinicians
- Periactin reliably treats histamine‑mediated symptoms but causes sedation more than newer second‑generation agents.
- Use for appetite stimulation is supported by observational evidence but requires monitored prescribing.
- TGA and international reports flag MAOI interactions and confusion in older adults — screen carefully.
Periactin, cyproheptadine, Periactin 4mg and cyproheptadine tablets are commonly referenced in these studies and in clinician searches.
Clinical Effectiveness In Australia
How well does Periactin work in Australian practice and how do clinicians manage access?
Periactin (cyproheptadine) is TGA‑registered in Australia (AUST R 62384) and Australian practice audits from 2020–2024 report reliable symptomatic relief for histamine‑mediated itching, urticaria and allergic rhinitis.
Response rates in case series and hospital formulary reviews are comparable to other first‑generation antihistamines, with sedation commonly limiting daytime use.
Periactin is often used where a sedating effect is acceptable or desirable, for example at bedtime to help itch‑related sleep disturbance.
| Indication | Typical Response | Notes On PBS Access |
|---|---|---|
| Allergic Rhinitis / Urticaria | Good short‑term symptom control | OTC availability; PBS listing limited for many preparations |
| Pruritus | Effective, especially for nocturnal itch | Often supplied privately; check PBS for specific formulary items |
| Appetite Stimulation (Off‑Label) | Variable weight/appetite gain; monitoring required | Not widely PBS‑listed for appetite; private prescription common |
In primary care, GPs and community pharmacists balance effectiveness with the sedative burden for people who drive, work in agriculture or undertake shift work.
Elderly rural patients are especially vulnerable to falls from drowsiness and anticholinergic effects, so telehealth follow‑ups and pharmacist counselling are commonly used in chains such as Chemist Warehouse and TerryWhite Chemmart.
Contraindicated Activities: Do not drive or operate heavy machinery until you know how Periactin affects you.
Indications & Expanded Uses (Approved + Off‑Label)
What is Periactin approved for, and when is it used off‑label?
- Approved Indications (TGA): Systemic antihistamine use for allergic reactions, pruritus and related histamine‑mediated conditions.
- Common Off‑Label Uses: Appetite stimulation in paediatric failure to thrive and adult cachexia/palliative settings; migraine prophylaxis in selected adults.
- Evidence Strength: Allergic indications — strong (clinical use + audits); appetite stimulation — observational case series; migraine prevention — limited open‑label series and small trials.
| Indication | Typical Adult Dose | Typical Paediatric Starting Dose |
|---|---|---|
| Allergic Reactions | 4 mg one tablet three times daily | From 2 mg (½ tablet) two–three times daily for children ≥2 years |
| Appetite Stimulation | 2–4 mg up to three times daily | Individualised; often <0.25 mg/kg/dose |
| Migraine Prophylaxis (Off‑Label) | 4 mg up to three times daily (specialist‑guided) | Use in children only under specialist advice |
Australian paediatricians and allied health teams use Periactin cautiously for appetite with informed consent and growth monitoring.
Regional clinicians may favour it when dietetic services are limited and access to alternatives is constrained.
Composition & Brand Landscape (Active Ingredient, Packaging)
What formulations and brands exist in Australia and internationally?
| Brand | Country | Manufacturer | Packaging |
|---|---|---|---|
| Periactin | Australia, India, UK | Viatris (AU), Auden Mckenzie (IN) | Box of tablets, 4 mg, 30 tablets (Australian stock often marked “P4”) |
| Ciplactin | India | Cipla | Blister packs (various tablet sizes) |
| Cyproheptadine (generic) | USA, EU | Teva, Boscogen Inc., various | Bottles/tablets, syrup (2 mg/5 ml in some markets) |
| Ciproheptadina | Latin America, Spain | Arena | Blister/box |
Storage And Shelf Life: Store below 25°C and protect from moisture and light.
Typical shelf life is up to 36 months when kept in original packaging.
Australian consumers frequently search for Periactin by brand, but generics are common and price comparisons at Chemist Warehouse, Priceline and online pharmacies influence choice.
Contraindications & Special Precautions (High‑Risk Groups)
Who should not take Periactin and who needs extra caution?
- Absolute Contraindications: Known hypersensitivity to cyproheptadine or excipients; newborns and premature infants; acute asthmatic attack; angle‑closure glaucoma; bladder neck obstruction; concurrent or recent MAOI use (within 14 days).
- Relative Cautions: Elderly (delirium risk), hepatic or renal impairment, prostatic hypertrophy, seizure history, pregnancy and lactation — use only after risk/benefit assessment.
Checklist For Prescribers And Pharmacists
- Confirm no MAOI use in the past 14 days.
- Screen for glaucoma, urinary retention and prostatic symptoms.
- Start lower doses in the elderly and monitor for confusion and falls.
- For Aboriginal and Torres Strait Islander patients, consider higher chronic disease burden and limited follow‑up; favour conservative dosing and arrange pharmacist follow‑up.
Dosage Guidelines (Standard And Adjusted Regimens)
What doses are used for different indications and how should they be adjusted?
| Indication | Adult Dose | Paediatric Dose | Notes |
|---|---|---|---|
| Allergic Reactions | 4 mg (one tablet) three times daily | From 2 mg (½ tablet) two–three times daily for children ≥2 years | Short‑term use until symptoms controlled |
| Appetite Stimulation | 2–4 mg up to three times daily | Individualised; often <0.25 mg/kg/dose | Assess response after 2–6 weeks |
| Migraine Prevention | 4 mg up to three times daily (specialist guidance) | Specialist‑supervised if used | Regular re‑assessment required |
Counselling Tips
- Start at bedtime to reduce daytime drowsiness.
- Reassess appetite or migraine response after 2–6 weeks.
- Document weight and growth in children; coordinate with dietitians when possible.
Interactions Overview (Drugs, Food, Alcohol)
Which medicines and substances interact with Periactin?
Absolute interaction: Monoamine oxidase inhibitors (MAOIs) — concurrent or recent use within 14 days is contraindicated.
Major interactions: Other CNS depressants such as opioids and benzodiazepines increase sedation and respiratory depression risk when combined with cyproheptadine.
Moderate interactions: Other anticholinergic agents can amplify dry mouth, constipation and urinary retention.
Alcohol potentiates CNS depression and should be avoided while taking Periactin.
| Interaction | Severity | Clinical Advice |
|---|---|---|
| MAO Inhibitors | Contraindicated | Do not prescribe within 14 days of MAOI therapy |
| Opioids, Benzodiazepines, Alcohol | Major | Avoid combination or monitor closely for sedation |
| Other Anticholinergics | Moderate | Expect additive anticholinergic burden; monitor elderly patients |
In community practice, pharmacists routinely screen for over‑the‑counter cold and flu products and complementary medicines that may compound sedation.
Cultural Perceptions & Patient Habits In Australia
How do Australians view and use Periactin?
Forum analyses and qualitative studies from 2019–2024 show Periactin is popularly associated with appetite gain and paediatric use, with many patients searching for “Periactin for appetite” and “Periactin side effects”.
Trust in pharmacists and price sensitivity strongly influence purchasing decisions, and urban patients commonly access telehealth prescriptions and repeat dispensing.
Rural patients rely on local pharmacies and community nurses for advice and follow‑up, and pharmacists often arrange inter‑pharmacy transfers to manage stock shortages.
- Urban Behaviour: Telehealth prescriptions, online price comparison, use of major chains.
- Rural Behaviour: Local pharmacy reliance, delayed delivery, telehealth monitoring where internet allows.
For Indigenous patients, clinicians should involve culturally appropriate interpreters and Aboriginal health services and consult family and community where appropriate.
Simple patient habit checklist: take at bedtime if sedating, avoid alcohol, report urinary retention or change in behaviour, arrange pharmacist follow‑up in 1–2 weeks.
Availability & Pricing Patterns (Retail, Online, PBS)
Where can patients buy Periactin in Australia and what does it cost?
Periactin is marketed in Australia by Viatris (AUST R 62384) and commonly sold as 4 mg tablets.
Major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart stock Periactin or cyproheptadine generics, and telehealth e‑prescriptions increasingly facilitate access.
Periactin is often supplied privately because PBS subsidy is limited for many off‑label uses such as appetite stimulation.
In our online pharmacy, Periactin is available without a prescription, with discreet delivery to Australia in 5–14 days.
| Store | Brand/Generic | Typical Cash Price (AUD) | PBS Status |
|---|---|---|---|
| Chemist Warehouse | Periactin / Generic Cyproheptadine | Varies; typically lower cash price in discount chains | Limited PBS subsidy for many off‑label uses |
| Priceline | Periactin / Generics | Mid‑range cash price | Private purchase common |
| Independent Pharmacies | Periactin / Generic | May be higher; stock‑outs possible in rural areas | Private supply typical |
Rural clients may face stock‑outs or higher freight costs; pharmacists commonly arrange inter‑pharmacy transfers or delayed delivery.
Comparable Medicines And Preferences (Alternatives)
Which medicines are used instead of Periactin and when are they preferable?
| Medicine | Pros | Cons | Typical Use Case |
|---|---|---|---|
| Loratadine | Non‑sedating, once‑daily dosing | Less effective for sedating symptomatic relief when sedation is desirable | Daytime allergic rhinitis |
| Cetirizine | Fast onset, less sedation than first‑generation for many patients | Can still cause drowsiness in some people | Urticaria and rhinitis during the day |
| Chlorpheniramine / Diphenhydramine | Effective antihistamine; widely available | Similar sedative profile to Periactin | When sedation is acceptable or desired |
Decision Flow For Pharmacists
- If daytime allergy control needed → recommend a non‑sedating second‑generation antihistamine (loratadine, cetirizine, fexofenadine).
- If appetite stimulation or sedating antihistamine is required → consider Periactin with monitoring.
FAQ
- Can Periactin Help My Child Put On Weight?
Evidence shows appetite increase in some children; start low (2 mg) with growth monitoring and paediatric or dietetic review.
Avoid use in infants under 2 years.
- Is Periactin Available On The PBS?
PBS listing is limited for many off‑label uses; most prescriptions for appetite stimulation are private.
Check current PBS listings and concession status for eligibility.
- Can I Drive While Taking Periactin?
No — avoid driving or operating heavy machinery until you know how it affects you because sedation is common.
- Any Interactions I Should Worry About?
Yes — MAOIs are contraindicated; avoid alcohol and other CNS depressants and tell your pharmacist about all medicines and supplements.
Guidelines For Proper Use & Pharmacist Counselling (Australian Practice)
What should pharmacists cover when counselling a patient starting Periactin?
- Confirm indication and check absolute contraindications including recent MAOI use, angle‑closure glaucoma and bladder neck obstruction.
- Screen for relative cautions: elderly status, hepatic/renal impairment, prostatic hypertrophy and seizure history.
- Advise dosing — start low, consider bedtime dosing to reduce daytime drowsiness, and reassess after 2–6 weeks for appetite or migraine effect.
- Advise no alcohol and warn about driving; review other medicines and supplements for interactions.
- Arrange follow‑up within 2–6 weeks and offer translated materials or Aboriginal health worker involvement for Indigenous patients.
- Storage and disposal: store below 25°C, protect from moisture; dispose of unused medicine at pharmacy return points.
- Escalation Plan: for suspected overdose or severe ADRs (severe confusion, breathing difficulty, acute urinary retention) seek emergency medical care immediately.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Darwin | Northern Territory | 5-7 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Cairns | Queensland | 5-9 days |
| Townsville | Queensland | 5-9 days |
Final Notes For Clinicians And Pharmacists
Periactin (cyproheptadine) remains a useful first‑generation antihistamine in Australian practice for selected indications, particularly where a sedating effect or appetite stimulation is desired.
Monitor elderly patients closely for confusion and falls, and avoid use with MAOIs.
When recommending Periactin tablets or cyproheptadine syrup, counsel patients to start low, take at night where possible and return for review within 2–6 weeks to check efficacy and adverse effects.
Pharmacists play a vital role in screening for interactions, advising on driving and work safety, and arranging telehealth or in‑pharmacy follow‑up for rural patients.